Clinical Trials & Research

/Clinical Trials & Research

The House Passes The 21st Century Cures Act – On To The Senate

Last Wednesday the House passed with a vote of 392 to 26, a medical innovation bill known as the 21st Century Cures Act, aimed at curing diseases, with the measure securing bipartisan support after months of negotiations. The bill’s goals are to speed up the Food and Drug Administration’s approval of new drugs while also investing new money in medical research. The package also includes a range of other healthcare priorities, including $1 billion over two years to fight the epidemic of opioid addiction and $1.8 billion for Vice President Biden’s cancer “moonshot.” The cures legislation also includes a mental health [...]

By | December 1st, 2016|Cancer Moon Shot, FDA, Politics of Cancer, Research, Uncategorized|0 Comments

Politics As Usual As Congress Prepares To Not Pass The Budget – A Potential Devastating Problem for Medical Research

It is deeply troubling  to learn that Congress is considering not completing the fiscal year 2017 budget appropriations process.  Because of the normal political fighting that we still see in Washington, Congress is now considering passing a short-term or even long-term budget continuing resolution instead of the negotiated budget resolution they have worked so hard and invested so many of our tax paid hours on creating. Moving in this direction would have devastating consequences for medical research, including the  Defense Health Research Programs at the Department of Defense (DoD) of which our own Prostate Cancer Research Program (PCRP) is a [...]

By | November 18th, 2016|advocacy, DOD, DOD PCRP, NIH, Research, Uncategorized|0 Comments

Vitamin D3 Potentiates Metformin in DU145 Human Prostate Cancer Cells

It is well established that common drugs like Metformin and vitamin D? exhibit a strong anti-proliferative action in many cancer cell lines. Recent research confirms that this is also true in human prostate cancer cells. In a recent study it was demonstrated that the combination of the two drugs, metformin and vitamin D3, had a much stronger positive effect on DU145 human prostate cancer cell growth than either drug alone. These two drugs showed a synergistic effect on cell proliferation and apoptosis. Most of us do not know the genetic structure of our cancer tumor, so we do not know [...]

By | November 17th, 2016|Metformin, Research, Vitamine D3|0 Comments

Oncotype DX® Now Validated for Adverse Pathology, Biochemical Recurrence, Metastasis and Prostate Cancer Specific Death

In a press release issued yesterday, Genomic Health Inc. announced topline results from their clinical validation study of its biopsy-based Oncotype DX® Genomic Prostate Score™ (GPS). The study met its primary endpoint by demonstrating that Oncotype DX® test is a strong predictor for the development of metastasis and also prostate cancer death in men with early-stage prostate cancer. The test evaluates the genetic makeup of tumor tissue taken from prostate biopsies. The Oncotype DX test has now been validated for adverse pathology, biochemical recurrence, metastasis and prostate cancer-specific death. According to a statement issued by Phil Febbo, M.D., the chief medical officer, Genomic Health, [...]

スーパーコピーブランド ロレックススーパーコピー オメガスーパーコピー ブルガリスーパーコピー ブライトリングスーパーコピー カルティエスーパーコピー シャネル時計コピー IWCスーパーコピー フランクミュラースーパーコピー パネライスーパーコピー タグホイヤースーパーコピー ウブロスーパーコピー ガガミラノスーパーコピー ルイヴィトンスーパーコピー シャネルスーパーコピー エルメススーパーコピー グッチスーパーコピー ボッテガヴェネタスーパーコピー プラダスーパーコピー セリーヌスーパーコピー ロレックススーパーコピー ウブロスーパーコピー